Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/29/2021 | $12.00 | Buy | Maxim Group |
STATEN ISLAND, N.Y., Jan. 7, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the closing of its previously announced registered direct offering of 2,463,058 shares of its common stock at a purchase price of $1.015 per share priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,463,058 shares of common stock. The warrants have an exercise price of $0.90 per share, are exercisable upon issuance and expire five yea
STATEN ISLAND, N.Y., Jan. 6, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,463,058 shares of its common stock at a purchase price of $1.015 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,463,058 shares of common stock. The warrants will have an exercise price of $0
Acurx has now received positive written responses from the EMA (European Medicines Agency) under its Scientific Advice Procedure that the clinical, non-clinical and CMC (Chemistry Manufacturing and Controls) information package submitted supports advancement of the ibezapolstat Phase 3 programThe responses also included guidance on ibezapolstat's regulatory pathway for a Marketing Authorization Application for ibezapolstat in CDIWith mutually consistent feedback from both EMA and FDA, Acurx is well positioned to commence our international Phase 3 registration programAcurx is also preparing to request regulatory guidance to initiate clinical trials in Japan, Canada and the United KingdomIbeza
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
SC 13G/A - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
Maxim Group initiated coverage of Acurx Pharmaceuticals with a rating of Buy and set a new price target of $12.00
D - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
424B5 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
STATEN ISLAND, N.Y., Nov. 13, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2024. Highlights of the third quarter ended September 30, 2024, or in some cases shortly thereafter, include: In July 2024, results from the ibezapolstat (IBZ) Phase 2 clinical trial in patients with C. difficile Infection (CDI) were presented at the 17th Biennial Congress of the Anaerobe Society of the Americas by Taryn A. Eubank, PharmD, BCIDP,
STATEN ISLAND, N.Y., Oct. 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late- stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its third quarter 2024 financial results on Wednesday, November 13, 2024 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Wednesday, November 13, 2024 Time:
STATEN ISLAND, N.Y., Aug. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2024. Highlights of the second quarter ended June 30, 2024, or in some cases shortly thereafter, include: In April 2024, we completed a successful End-of-Phase 2 Clinical Meeting with FDA and confirmed Phase 3 Readiness for ibezapolstat (IBZ) to enter Phase 3 clinical trials for the treatment of C. difficile infection. Agreement with FDA was reached